C1 inhibitor deficiency

Urticaria and Angioedema

Volumn , Issue , 2004, Pages 303-320

  Kaplan, Allen P ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 34249667418     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (86)

1. Schreiber AD, Kaplan AP, Austen KF. Inhibition by Cl INH of Hageman factor fragment activation of coagulation, fibrinolysis, and kinin generation. J Clin Invest 1973; 52:1402-1409.
2. Pixley RA, Schapira M, Colman RW. The regulation of factor XII by plasma proteinase inhibitors J BioI Chem 1985; 260:1723-1729
3. 2macroglobulin-kallikrein complexes. J Biol Chem 1985; 260:4257-4263
4. Donaldson YH, Evans RR. A biochemical abnormality in hereditary angioneurotic edema. Am J Med 1963: 35:37-44.
5. Kramer J, Katz Y, Rosen FS, Davis, AE., III, Strunk RC. Synthesis of CI inhibitor in fibroblasts from patients with Type I and Type 11 hereditary angioneurotic edema. J C1in Invest 1991; 87:1614-1620.
6. Cladwell JR, Ruddy S, Schur P, Austen KF. Acquired Cl inhibitor deficiency in Iynwhosarcoma. Clin Immunollmmunopathol 1972; 1:39-52.
7. Hauptmann G, Lang JM, North ML, Oberling F, Mayer G, Lachmann PG. Acquired Cl inhibitor deficiencies in Iymphoproliferative diseases with serum immunoglobulin abnormalities. Blut 1976; 32: 155-206.
8. Schreiber RD, Zweiman B, Atkins P, Goldwein F, Pietra G, Atkinson B, Abdou NI. Acquired angioedema with Iymphoproliferative disorder association of CI inhibitor deficiency with cellular abnormality. Blood 1976; 48:567-580.
9. Alsenz J, Bork K, Loos M. Autoantibody-mediated acquired deficiency of Cl inhibitor. N Engl J Med 1987; 316: 1360-1366.
10. Zuraw BL. Curd JG. Demonstration of modified inactive first component of complement (Cl) inhibitor in the plasmas of Cl inhibitor deficient patients. J Clin Invest 1986; 78:567-575.
11. Malbran A. Hammer CH, Frank MM, Fries LF. Acquired angioedema: observations in the mechanisms of action of auto antibodies directed against CI esterase inhibitor. J Allergy Clin Immunol 1988; 81:1199-1204.
12. Pearson KD, Buchignani JS, Shimkin PM, Frank MM. Hereditary angioneurotic edema of the gastrointestinal tract. Am J Roentgenol Radium Ther Nucl Med 1972; 116:256-261.
13. Sheffer AL, Craig JM, Willms-Kretschmer K. Histopathological and ultrastructural observations on tissues from patients with hereditary angioneurotic edema. J Allergy 1971; 47:292-297.
14. Tosi M. Molecular genetics of Cl inhibitor. Immunobiology 1998; 199:358-365.
15. Quastel M, Harrison R, Cicardi M, Alper CA, Rosen FS. Behavior in vivo of normal and dysfunctional Cl inhibitor in normal subjects and patients with hereditary angioedema. J C1in Invest 1983; 71: 1041-1046.
16. Kramer J, Katz Y, Rosen FS, Davis III AE, Strunk RC. Synthesis of Cl inhibitor in fibroblasts from patients with Type I and Type II hereditary angioneurotic edema. J Clin Invest 1991; 87:1614-1620.
17. Kramer J, Rosen RS, Colter, H R, Rajezy K, Strunk AC. Transinhibition of CI inhibitor synthesis in Type I hereditary angioneurotic edema. J Clin Invest 1993; 91:1258-1262
18. Ruddy S, Gigli I, Sheffer AL, Austen KF. The laboratory diagnosis of hereditary angioedema. In: Rose N. Richter M, Sehon A, et al., eds. Allergology: Proceedings of the Sixth International Congress of Allergology. Amsterdam: Excerpta Medica, 1968:351-359.
19. Zuraw BL, Sugimoto S, Curd JG, The value of rocket immunoelectrophoresis for C4 activation in the evaluation of patients with angioedema or Cl inhibitor deficiency. J Allergy Clin Immunol 1986; 78:1115-1120.
20. Austen KF, Sheffer AL. Detection of hereditary angioneurotic edema by demonstration of a reduction in the second component of human complement. N Engl J Med 1965; 272:649-656.
21. Rose FS, Alper CA, Pensky J, Klemperer RM, Donaldson VH. Genetic heterogeneity of the Cl esterase inhibitor in patients with hereditary angioneurotic edema. J C1in Invest 1971; 50:2143-2149.
22. Klemperer M R, Donaldson VH, Rosen FS. The vasopermeability response in man to purified Cl esterase J Clin Invest 1968; 47:604 (abstract).
23. Donaldson VH. Mechanisms of activation of Cl esterase in hereditary angioneurotic edema plasma in vitro: the role of Hageman factm, a clotpromoting agent. J Exp Med 1968; 127:411-429.
24. Donaldson VH, Rosen FS, Bing DH. Role of the second component of complement (C2) and plasmin in kinin release in hereditary angioneurotic edema (H.AN.E.) Plasma Trans Assoc Am Physicians 1977; 40:174-183.
25. Curd JG, Yelvington M, Burridge N. Generation of bradykinin during incubation of hereditary angioedema plasma. Mol Immunol 1983; 19:1365.
26. Fields T, Ghebrehiwet B, Kaplan AP. Kinin formation in hereditary angioedema plasma: evidence against kinin derivation from C2 and in support of "spontaneous" formation of bradykinin. J Allergy Clin Immunol 1983; 72:54-60.
27. Strang CJ, Cholin S, Spragg J, Davis III AE, Schneeberger EE, Donaldson VH, Rosen FS. Angioedema induced by a peptide derived from complement component Cl. J Exp Med 1988; 168:1685-1698.
28. Shoemaker LR, Schurman SJ, Donaldson VH, Davis III AE, Hereditary angioneurotic edema: characterization of plasma kinin and vascular permeability- enhancing activities. C1in Exp Immunol 1994; 95:22-28.
29. Carpenter CB, Ruddy S, Shehadeh IH, Muller-Eberhard HJ, Merrill JP, Austen KF. Complement metabolism in man: hypercatabolism of the fourth (C4) and third (C3) components in patients with real allograft rejection and hereditary angioedema. J Clin Invest 1969; 48: 1495-1505.
30. Silverberg M, Dunn JT, Garen L, Kaplan AP. Autoactivation of human Hageman Factor: demonstration utilizing a synthetic substrate. J Bioi Chem 1980; 255:7281-7286.
31. Silverberg M, Kaplan AP. Enzymatic activities of activated and Zymogen forms of Hageman Factor (Factor XII). Blood 1982; 60:64-70.
32. Tankersly DL, Finlayson JS. Kinetics of activation and autoactivation of human Factor XII. Biochem 1984; 23:273-279
33. Schmaier AH, Kuo A, Lundberg D, Murray S, Cines DB. The expression of high molecular weight kininogen on human umbilical vein endothelial cells. J Biol Chem 1988; 263: 16327-16333.
34. van Iwaarden F, DeGroot PG, Bouma BN. The binding of high molecular weight kininogen to cultured human endothelial cells. J Biol Chem 1988; 263:4698-4703
35. Mandie RJ Jr., Kaplan AP. Hageman Factor substrates I. Human plasma prekallikrein. Mechanism of activation by Hageman Factor and participation in Hageman Factor-dependent fibrinoloysis. J Biol Chem 1977; 252:6097.
36. Cochrane CG, Revak SO, Wuepper KD. Activation of Hageman Factor in solid and fluid phase. J Exp Med 1973; 135: 1564-1583
37. Dunn JT, Silverberg M, Kaplan AP. The cleavage and formation of activated Hageman Factor by autodigestion and by kallikrein. J Biol Chem 1982; 257:1779-1784.
38. Ichinose A, Fujikawa K, Suyama T. The activation of prourokinase by plasma kallikrein and its inactivation by thrombin. J Biol Chem 1986; 261:3486-3489.
39. Juhlin L, Michaelsson G Vascular reactions in hereditary angioedema. Acta Derm Venereol 1969; 49:20-25.
40. Talamo RC, Haber E, Austen KF. A radioimmunoassay for bradykinin in plasma and synovial fluid. J Lab Clin Med 1969; 74:816-827.
41. Nussberger J, Cugno M, Amstutz C. Cicardi M, Pellacani A, Agostoni A. Plasma bradykinin in angioedema. Lancet 1998; 351: 1693-1697.
42. Ratnoff OD, Naff GB. The conversion of CNIS to CNl esterase by plasmin and trypsin. J Exp Med 1967; 125:337-358.
43. Ghebrehiwet B, Silverberg M, Kaplan AP. Activation of the classical pathway of complement by Hageman Factor fragment (HFf). J Exp Med 1981; 153:665-676
44. Ghebrehiwet G, Randazzo BP, Dunn JT, Kaplan AP. Mechanism of activation of the classical pathway of complement by Hageman Factor fragment. J Clin Invest 1983: 71:1450-1456.
45. Curd JG, Prograis LF Jr, Cochrane CG. Detection of active kallikrein in induced blister fluids of hereditary angioedema patients. J Exp Med 1980: 152:742-747
46. Schapira M, Silver LD, Scott CF, Schmaier AH, Prograis LJ Jr., Curd JC, Colman RW. Prekallikrein activation and high molecular weight kininogen consumption in hereditary angioedema. N Engl J Med 1983: 308:1050-1053.
47. 443→ Val substitution and functional analysis of the recombinant mutant protein. I C1in invest 1995: 95: 1299-1305.
48. Zahedi R, Wisnieski, J, Davis III AE. Role of the P2 residue of complement I inhibitor (Ala 443) in determination of target protease specificity: inhibition of complement and contact proteases. J Immunol 1997: 159:983-988.
49. Cugno M, Cicardi M, Coppola R, Agostini A. Activation of Factor XII and cleavage of high molecular weight kininogen during acute attacks in hereditary and acquired Cl inhibitor deficiencies. Immunopharmacology 1996: 33361-364.
50. Nussberger J, Cugno M, Cicardi M, Agostoni A. Local bradykinin generation in hereditary angioedema. J Allergy Clin Immunol 1999; 104:1321-1322.
51. Kaplan AP, Austen KF. A prealbumin activation of prekallikrein II. Derivation of activators of prekallikrein from activated Hageman Factor with plasmin. J Exp Med 1971: 133:696-712.
52. Wallace EM, Perkins SJ, Sim RB, Willis AC, Feigberg C, Jackson J Degradation of Cl-inhibitor by plasmin: implications for the control of inflammatory processes. Mol Med 1997; 3:385-396.
53. Joseph K, Shibayama Y, Ghebrehiwet B, Kaplan AP. Factor XII-dependent contact activation on endothelial cells and binding proteins gClqR and cytokeratin I. Thromb Haemost 2001; 85:119-124.
54. Caldwell JR, Ruddy S, Schur P, Austen KF. Acquired Cl inhibitor deficiency in lymphosarcoma. Clin Immunol Immunopathol 1972: 1:39-52.
55. Hauptmann G, Lang JM, North ML, Oberling F, Mayer G, Lachmann PJ Acquired Cl inhibitor deficiencies in lymphoproliferative diseases with serum immunoglobulin abnormalities. Blut 1976: 32: 195-206.
56. Schreiber AD, Zweiman B, Atkins P, Goldwein F, Pietra G, Alkinson B, Abdou NI. Acquired angioedema with lymphoproliferative disorder association of Cl inhibitor dclicicncy with cellular abnormality. Blood 1976: 48:567-580.
57. Geha RS, Quinti I. Austen KF. Cicardi M, Sheila A, Rosen FS. Acquired CJ-inhibitor deficiency associated with antiidiotypic antibody to monoclonal immunoglobulin. N Engl J Med 1985: 312:534.
58. Donaldson YH, Hess EY, McAdams PJ. Lupus-erythematosus-like disease in three unrelated women with hereditary angioneurotic edema. Ann Intern Med 1977: 86312-313.
59. Cohen SH, Koethe SM, Kozin F, Rodey G, Arkins JA, Fink JN. Acquired angioedema associated with rectal carcinoma and its response to danazol therapy. J Allergy C1in Immunol 1978; 62:217-221.
60. Jackson J, Sim RB, Whelan A, Feighery C. An IgG autoantibody which inactivates Cl inhibitor Nature 1986; 323:722-724.
61. Alsenz J, Bork K, Loos M. Autoantibody-mediated Clcquired deficiency of Cl inhibitor. N Engl J Med 1987; 313:1360-1366.
62. Malbran A, Hammer CH, Frank MM, Fries LF. Acquired angioedema: observations on the mechanism of action of autoantibodies directed against Cl esterase inhibitor J Allergy Clin Immunol 1988; 81:1199-1204.
63. Jackson J, Sim RB, Whaley K, Feighery C. Autoantibody facilitated cleavage of Cl inhibitor in autoimmune angioedema. J Clin Invest 1989; 83:698-707
64. He S, Sim RB, Whaley K. Mechanism of action of anti CI inhibitor auto antibodies: prevention of the formation of stable ClS-Cl INH complexes. Mol Med 1998; 4119-128.
65. Binkley KE, Davis III AE. Clinical, biochemical, and genetic characterization of a novel estrogen-dependent inherited form of angioedema. J Allergy Clin Immunol 2000; 106:546-550
66. Cicardi M, Beretta A, Colombo M, Gioffre D, Cugno M, Agostoni A. Relevance of lymphoproliCerative disorders and anti Cl inhibitor autoantibodies in acquired angioedema. Clin Exp Immunol 1996: 106:475-480.
67. Chevailler A, Orland G, Ponard D, Pernollet M, Carrere F, Renser G, Drouet M, Hurez D, Gardais J. Cl inhibitor binding monoclonal immunoglobulins in three patients with acquired angioneurotic edema. J Allergy Clin Immunol 1996; 97998-1008
68. Gelfand JA, Sherin RJ, Alling OW, Frank MM. Treatment of hereditary angioedema with danazol; reversal of clinical and biochemical abnormalities. N Engl J Med 1976; 295:1444-1448
69. Sheffer AL, Fearon DT, Austen KF. Clinical and biochemical effects of stanazolol therapy for hereditary angioedema J Allergy Clin Immunol 1981; 68:181-187
70. Warin AP, Greaves MW, Gatecliff M, Williamson OM, Warin RP. Treatment of hereditary angioedema by low-dose attenuated androgens: dissociation of clinical response from levels of Cl esterase inhibitor and C4. Br J Dermatol 1980; 103:405-409
71. Sheffer AL, Fearon DT, Austen KF. Hereditary angioedema: a decade of management with stanozolol. J Allergy Clin Immunol 1987; 80:855-860.
72. Gadek JE. Hosea SW, Gellfand JA, Frank MM. Response of variant hereditary angioedema phenotypes of danazol therapy. J Clin Invest 1979; 64:280-286.
73. Hosea SW, Santaella ML, Brown EJ, Burger M, Katusha K, Frank MM. Long term therapy of hereditary angioedema with Danazol. Ann Intern Med 1990; 93809-812.
74. Cicardi M. Bergamaschini L, Cugno M. Hack E, Agostoni G, Agostoni A. Long term treatment of hereditary angioedema with attenuated androgens: a survey of a 13-year experience. J Allergy C1in Immunol 1991; 87:768-773.
75. Cicardi M. Castelli R, Zingale LC, Agostoni A. Side effects of long-term prophylaxis with attenuated androgens in hereditary angioedema: comparison of treated and untreated patients. J Allergy Clin Immunol 1997; 99: 194-196.
76. Frank MM, Sergent JS, Kane MA, Alling DW. e-aminocaproic and therapy of hereditary angioneurotic edema: a double blind study. N Engl J Med 1972; 286:808-812.
77. Lundh B, Laurell A. Wetterqvist H, White T. Granerus G. A case of hereditary angioneurotic edema successfully treated with e-aminocaproic acid. Clin Exp Immunol 1968; 3:733-745.
78. Shetler AL, Austen KF, Rosen FS. Tranexamic acid therapy in hereditary angioneurotic edema. N Engl J Med 1972; 287:452-454.
79. Soter NA, Austen KF, Gigli I. Inhibition by e-aminocaproic acid of the activation of the nrst component of the complement system. J Immunol 1975; 114:928-932
80. Gadek JE, Hosea SW, Glefand JA, Santaella M, Wickerhauser M, Triantaphyllopoulos DC, Frank MM. Replacement therapy in hereditary angioedema: successful treatment of acute episodes with partly purified Cl inhibitor. N Engl J Med 1980; 302:542-546
81. Visentin DE, Yang WH, Karsh J. Cl esterase inhibitor transfusion in patients with hereditary angioedema. Ann Allergy Asthma Immunol 1998; 80:457-461.
82. Cugno M, Cicardi M, Agostoni A. Activation of the contact system and fibrinolysis in autoimmune acquired angioedema: a rationale for prophylactic use of tranexamic acid. J Allergy Clin Immunol 1994; 93:870-876.
83. Metzger WJ, Kaplan AP, Irons J, Patterson R. Hereditary vibratory angioedema: Confirmation of histamine release in a type of physical hypersensitivity. J Allergy Clin Immunol 1976: 57:605-608.
84. Patterson R, Mellies CJ, Blankenship ML, Pruzansky JJ. Vibratory angioedema: a hereditary type of physical hypersensitivity. J Allergy Clin Immunol 1972; 50: 174-182.
85. Cicardi M, Bergamaschini L, Zingale LC, Gioffre D, Agostoni A. Idiopathic nonhistaminergic angioedema. Am J Med 1999; 106:650-654.
86. Sheikh L, Kaplan AP. The mechanism of digestion of bradykinin and Iysyl bradykinin (kallidin) in human serum: The role of carboxypeptidase. angiotension converting enzyme, and determination of final degradation products. Biochem Pharmacol 1989: 38:993-1000.